Hypoxia: Targeting the tumour

Anti-Cancer Agents in Medicinal Chemistry

Volumn 6, Issue 4, 2006, Pages 281-286

  Boyle, Robert George ^a   Travers, Stuart ^a  

^a Sentinel Oncology   (United Kingdom)

Author keywords

Bioreduction; Hypoxia; Tumour targeting

Indexed keywords

1,4 BIS[[2 (DIMETHYLAMINO N OXIDE)ETHYL]AMINO] 5,8 DIHYDROXYANTHRAQUINONE; 5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; 5 (1 AZIRIDINYL) 3 HYDROXYMETHYL 2 (3 HYDROXY 1 PROPENYL) 1 METHYL 4,7 INDOLEDIONE; 90 CE; ANTINEOPLASTIC AGENT; AROMATIC NITRO COMPOUND; CAMPTOTHECIN DERIVATIVE; CISPLATIN; COMBRETASTATIN; CYTOCHROME P450 2B6; CYTOCHROME P450 3A4; DNA; KS 119; METRONIDAZOLE; MISONIDAZOLE; MITOMYCIN C; NITROIMIDAZOLE DERIVATIVE; NLCQ 1; OXIDE; OXYGEN; PORFIROMYCIN; PROTEIN P53; QUINONE DERIVATIVE; RH 1; TIRAPAZAMINE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BLADDER CANCER; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CYTOTOXICITY; DNA DAMAGE; DRUG HALF LIFE; DRUG MECHANISM; DRUG RESEARCH; DRUG STRUCTURE; DRUG TARGETING; GENE MUTATION; GENETIC REGULATION; HEAD AND NECK CANCER; HUMAN; HYPOXIA; MALIGNANT NEOPLASTIC DISEASE; METASTASIS POTENTIAL; MOUSE; NONHUMAN; PHENOTYPE; RADIOSENSITIVITY; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR VASCULARIZATION;

ANTHRAQUINONES; ANTINEOPLASTIC AGENTS; AZIRIDINES; BENZOQUINONES; CELL HYPOXIA; CLINICAL TRIALS, PHASE III; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; IMIDAZOLES; INDOLEQUINONES; NEOPLASMS; PRODRUGS; QUINOLINES; RADIATION-SENSITIZING AGENTS; TRIAZINES;

EID: 33745853839     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152006777698169     Document Type: Review

References (53)

1. Astrazeneca 2004 annual report.
2. Druker, B.J. Curr. Cancer Targets, 2001, 1, 49-57.
3. Ross, J.S. Clin. Leadership Management Rev. J. CLMA, 2003, 17(6), 333-340.
4. Gray, L.H.; Conger, A.D.; Ebert M.; Hornsey, S.; Scott, O.C. Br. J. Radiol., 1953, 26, 638-648.
5. Thomlinson, R.H.; Gray, L.H. Br. J. Cancer, 1955, 9, 539-549.
6. Hockel, M.; Vaupel, P. J. Natl. Cancer Inst., 2001, 93, 266-276.
7. Brown, J.M.; Giaccia, A.J. Cancer Res., 1998, 58, 1405-1416.
8. Tannock, I.F. Clin. Cancer Res., 2002, 8, 878-884.
9. Moeller, B.J.; Dreher, M.R.; Rabbani, Z.N.; Schroeder, T.; Cao, Y.; Li C.Y.; Dewhirst, M.W. Cancer Cell, 2005, 2(8), 99-110.
10. (b) Moeller B. J.; Dewhirst, M.W. Cell Cycle, 2004, 3(9), 1107-1110.
11. (c) Cao Y; Li C.Y.; Moeller, B. J.; Yu, D; Zhao, Y; Dreher, M. R.; Shan, S; Dewhirst, M. W. Cancer Res., 2005, 65 (13), 5498-5505.
12. (d) Moeller, B. J.; Cao, Y; Vujaskovic, Z; Li, C. Y.; Haroon, Z. A.; Dewhirst, M. W. Semin. Radiat. Oncol., 2004, 14 (3), 215-221.
13. Graeber, T.G.; Osmanian, C.; Jacks, T.; Housman, D.E.; Koch, C.J.; Lowe S.W.; Glaccia, A.J. Nature, 1996, 379, 88-91.
14. Harris, A.L., Nat Rev Cancer, 2002, 2(1), 38-47.
15. Bardos, J.I.; Ashcroft, M. Biochim. Biophys. Acta, 2005, 1755(2), 107-120.
16. Dales, J.; Garcia, S.; Meunier-Carpentier, S.; Andrac-Meyer, L.; Haddad, O.; Lavaut, M.; Allasia, C.; Bonnier, P.; Charpin, C. Intern. J. Cancer, 2005, 116(5), 734-739.
17. Williams,K.J.; Tefler, B.A.; Xenaki, D.; Sheridan, M.R.; Desbaillets, I.; Peters, H.J.W.; Honess, D.; Harris, A.L.; Dachs, G.U.; Van der Kogel, A.; Stratford, I.J. Radiother. Oncol., 2005, 75(1), 89-98.
18. Kunz, M.; Ibrahim, S.M. Mol. Cancer, 2003, 2, 23-36.
19. Denny, W.A. Expert Opin. Ther. Patents, 2005, 15(6), 635-646.
20. Brown, J.M.; Wilson, W.R. Nat. Rev. Cancer, 2004, 4, 437-447.
21. Denny, W.A. Cancer Invest., 2004, 4, 604-619.
22. Denny, W.A.; Wilson, W.R. Exp. Opin. Invest. Drugs, 2000, 9(12), 2889-2901.
23. Brown, J.M. Mol. Med. Today, 2000, 6, 157-161.
24. Rischin, D.; Peters, L.; Fisher, R.; Macann, A.; Denham, J.; Poulsen, M.; Jackson, M.; Kenny, L.; Penniment M.; Corry, J.; Lamb, D.; McClure, B. J. Clin. Oncol., 2005, 23, 79-87.
25. Hicks, K.O.; Siim, B.G.; Pruijn, F.B.; Wilson, W.R. Radiat. Res., 2004, 161(6), 656-666.
26. Anderson, R.F.; Shinde, S.S.; Hay, M.P.; Gamage, S.A.; Denny, W.A. Org. Biomol. Chem., 2005, 3, 2167-2174.
27. Siim, B.G.; Pruijn, F.B.; Sturman, J.R.; Hogg, A.; Hay, M.P.; Brown, J.M.; Wilson, W.R. Cancer Res., 2004, 64, 736-742.
28. Priyadarsini, K.I.; Tracy, M.; Wardman, P. Free Radic. Res., 1996, 25, 393-399.
29. Hay, M.P.; Gamage, S.A.; Kovacs, M.S.; Pruijn, F.B.; Anderson, R.F.; Patterson, A.V.; Wilson, W.R.; Brown, J.M.; Denny, W.A. J. Med. Chem., 2003, 46, 169-182.
30. Lipinski, C.A. Drug Discov. Today, 2003, 8(1), 12-6.
31. Tannock, I.F.; Carol, M.L.; Tunggal, J.K.; Cowan, D.S.M.; Egorin, M.J. Clin. Cancer Res., 2002, 8, 878-884.
32. Pruijin, F.B.; Sturman, J.R.; Liyanage, H.D.S.; Hicks, K.O.; Hay, M.P.; Wilson, W.R. J. Med. Chem., 2005, 48, 1079-1087.
33. Brown, M.J.; Peters, K.B. Cancer Res., 2002, 62, 5248-5253.
34. Chowdhury, G.; Kotandenyiya, D.; Daniels, J.S.; Barnes, C.L.; Gates, K.S. Chem. Res. Toxicol., 2004, 11, 1399-1405.
35. Azqueta, A.; Pachon, G; Cascante, M.; Creppy, E.E.; Lopez de Cerain, A. Mutagenesis, 2005, 20(3), 165-171.
36. Masunga, S.; Nagasawa, H.; Uto, Y.; Hori, H.; Ohnishi, K.; Takahashi, A.; Ohnishi, T.; Suzuki, M.; Nagata, K.; Kinashi, Y.; Ono, K. Oncol. Reports, 2005, 14(2), 393-400.
37. Raleigh, S. M.; Wanogho, E.; Burke, M. D.; Patterson, L. H. Xenobiotica, 1999, 29(11), 1115-22.
38. McCarhty, H.O.; Yakkundi, A.; McErlane, V.; Hughes, C.M,; Keilty, G.; Murray, M.; Patterson, L.H.; Hirst, D.G.; McKeown, S.R.; Robson, T. Cancer Gene Ther., 2003, 10(1), 40-48.
39. McErlane, V.; Yakkundi, A.; McCarthy, H.O.; Hughes, C.M,; Patterson, L.H.; Hirst, D.G.; Robson, T.; McKeown, S.R. J. Gene Med., 2005, 7(7), 851-859.
40. Haffty, B.G.; Son, Y.H.; Wilson, L.D.; Papac, R.; Fischer, D.; Rockwell, S.; Sartorelli, A.C.; Ross, D.; Sasaki, C.T.; Fischer, J.J. Radiat. Oncol. Investig., 1997, 5(5), 235-45.
41. Danson, S.; Ward, T.H.; Butler, J.; Ranson, M. Cancer Treat. Revi., 2004, 30(5), 437-449.
42. Phillips, R.M.; Mohammed, J.; Maitland, D.J.; Loadman, P.M.; Shnyder, S.D.; Steans, G.; Cooper, P.A.; Race, A.; Patterson, A.V.; Stratford, I.J. Biochem. Pharmacol., 2004, 68(11), 2107-2116.
43. Dehn, D.L.; Winski, S.L.; Ross, D. Clin.Cancer Res., 2004, 10(9), 3147-3155.
44. Kim, J.Y.; Patterson, A.V.; Stratford, I.J.; Hendry, J.H. Anti-Cancer Drugs, 2004, 15(1), 71-77.
45. Tudor, G.; Alley, M.; Nelson, C.M.; Huang, R.; Covell, D.G.; Gutierrez, P.; Sausville, E.A. Anti-Cancer Drugs, 2005, 16(4), 381-391.
46. Dische, S.; Saunders, M.I.; Anderson, P.; Stratford, M.R.; Minchinton, A. Int. J. Radiat. Oncol. Biol.Phys.,1982, 8, 335-338.
47. Denny, W.A.; Wilson W.R. J. Med. Chem., 1986, 29, 879-887.
48. Papadopoulou, M.V.; Bloomer, W.D. Clin. Cancer Res., 2003, 9, 5714-5720.
49. Palmer, D.H.; Mautner, V.; Hull, D.; Ellis, J.; Mountain, A.; Searle, P.; Young, L.S.; Gerritsen, W.; James, N.D.; Kerr, J.D. J. Clin. Oncol., 2005 ASCO Annual Meeting Proceedings, Vol. 23, No. 16S (June 1 Supplement), 3157.
50. Helsby, N.A.; Ferry, D.M.; Patterson, A.V.; Pullen, S.M.; Wilson, W.R. Br. J. Cancer, 2004, 90(5), 1084-1092.
51. Davis, P.D.; Naylor, M.A.; Thompson, P.; Everett, S.A.; Stratford, M.R.L.; Wardman, P. WO2004085421.
52. Zhang, Z.; Tanabe, K.; Hatta, H.; Nishimoto, S.; Org. Biol. Chem., 2005, 3(10), 1905-1910.
53. Seow, H.A.; Penketh, P.G.; Shyam, K.; Rockwell, S.; Sartorelli, A.C. PNAS, 2005, 102(26), 9282-9287.